AVAC Report
For nearly 15 years, AVAC has published an annual review of biomedical prevention research. Over this period, the focus of the AVAC Report has expanded from AIDS vaccine research alone to the full spectrum of options, including pre-exposure prophylaxis, microbicides, male circumcision and HSV-2 treatment. This comprehensive document reviews progress, makes recommendations and analyzes emerging issues.
Visit our AVAC Report Archive to view the AVAC Reports from 1998-2009
AVAC Report 2010: Turning the
Page
In each chapter we address a critical question facing the field as it writes the next chapter: What needs to happen next to ensure that the vaccine field capitalizes on the momentum from the Thai Prime-Boost trial? (Chapter One); How successful was community engagement in the largest AIDS vaccine trial in history? (Chapter Two); Is the AIDS vaccine field doing all that it can with the data and materials it has amassed or aims to collect? (Chapter Three); What kinds of trials will provide answers to the complex questions emerging in the microbicide, PrEP and vaccine fields? (Chapter Four); Is the world ready for the promise and pitfalls of ARV-based prevention strategies for HIV-positive and HIV-negative people? (Closing section). Turning the Page (full report)
Turning the Page (Thai)
What Belongs in the Next Chapter
- A letter from the Executive Director
- AVAC’s Top Recommendations for 2010 and Beyond
- Status Report: An update on last year’s recommendations
Chapter One - “Proof
of Concept” and its Consequences: Making
sense of the post-RV144
world
- Basics of RV144
- RV144 Results
- RV144 Trial Locations
- RV144: A Brief History
- Moment of Truth: Action and accountability for the Enterprise
Chapter Two - The Thai
Way Forward: What comes after the largest AIDS
vaccine trial in the
world?
Chapter Three - Data
and Materials: A “to-do” list for the
future
- Intellectual Property and Access: Revisiting our 2005 recommendations
- Data and Materials: Defining the terms
Chapter
Four - Trials and Trial Design: Where does
prevention research go from
here?
Closing - Speak
with One Voice, Work Towards One
Goal
AVAC’s Global Partners in Prevention Research Advocacy
Boxes, Figures and Tables
- Turning the Page: The need to diversify funding sources
- Turning the Page: Applying lessons from recent trials
- Turning the Page: Engaging new talent in the search for an AIDS vaccine
- Turning the Page: Innovation in prevention packages
- Adaptive Trials versus Classical Trials: A highly-optimistic comparison
- AVAC’s Web-based Resources
- What is Community Engagement?
- Learning our Lessons on Community Engagement: Another trial, another lesson?
- Sharing the Search for Clues: Step and RV144 post-trial analysis
- Sticking to It: Keeping up with the challenges of adherence
- Ongoing ARV-based Prevention Trials (as of June 2010)
- The Global AIDS Response: Five Current Myths Versus Current Realities
A preview of AVAC Report 2010 featuring an excerpt of The Thai Way Forward
This special excerpt of AVAC Report
2010: Turning the Page includes a
provocative, on-the-ground article about RV144,
also known as the Thai Prime-Boost study, which
provided evidence that an AIDS vaccine is
possible. This piece looks at some of the
questions and reactions that this landmark
study raised for the Thai participants,
scientists and advocates.
The full
AVAC Report 2010, published in July,
reviews the broader state of—and debates
around—AIDS vaccines and other HIV prevention
research. For this special preview, the release
of which coincides with HIV Vaccine Awareness
Day 2010, we focus on Thai voices because
perspectives from the countries where efficacy
trials take place should be front and center.
We’ve titled this year’s
Report Turning the Page, because we
see the Thai trial result as starting a new
chapter for AIDS vaccine research. In this
excerpt, and in the full Report, AVAC lays out
some of the things that we hope will part of
the story that’s still to come.